Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
Analysis of laboratory parameters before the occurrence of hepatic sinusoidal obstruction syndrome in children, adolescents, and young adults after hematopoietic stem cell transplantationJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05561-wDigital Resources/Online E-Resources |
2 |
Material Type: Article
|
![]() |
Incidence of second malignancies in patients with thymic carcinoma and thymic neuroendocrine tumorJournal of cancer research and clinical oncology, 2025-01, Vol.150 (1) [Peer Reviewed Journal]The Author(s) 2024 ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-023-05522-3Digital Resources/Online E-Resources |
3 |
Material Type: Article
|
![]() |
Adoption of management practices and impacts on major diseases among mandarin growers in Syangja, NepalCogent food & agriculture, 2024-12, Vol.10 (1) [Peer Reviewed Journal]EISSN: 2331-1932 ;DOI: 10.1080/23311932.2024.2344399Full text available |
4 |
Material Type: Article
|
![]() |
Changes of influenza vaccination rate and associated influencing factors after the COVID-19 pandemic in Shanghai, ChinaHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2287294-2287294 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2023.2287294 ;PMID: 38299510Full text available |
5 |
Material Type: Article
|
![]() |
Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, JapanHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2322795-2322795 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2322795 ;PMID: 38517220Full text available |
6 |
Material Type: Article
|
![]() |
Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine: CommentHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2306032-2306032 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2306032 ;PMID: 38258525Full text available |
7 |
Material Type: Article
|
![]() |
Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling studyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2348839-2348839 [Peer Reviewed Journal]2024 GlaxoSmithKline. Published with license by Taylor & Francis Group, LLC. 2024 GlaxoSmithKline ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2348839 ;PMID: 38804600Full text available |
8 |
Material Type: Article
|
![]() |
The risk of acute disseminated encephalomyelitis (ADEM) following covid-19 vaccination in England: A self-controlled case-series analysisHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2311969-2311969 [Peer Reviewed Journal]2024 Crown Copyright. Published with license by Taylor & Francis Group, LLC. 2024 Crown Copyright ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2311969 ;PMID: 38299507Full text available |
9 |
Material Type: Article
|
![]() |
Characteristics of measles antibodies in premature infants: CommentHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2352279-2352279 [Peer Reviewed Journal]ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2352279 ;PMID: 38754017Full text available |
10 |
Material Type: Article
|
![]() |
Rotavirus vaccine dose-two dropout and its associated factors among children who received rotavirus vaccine dose-one in Sub-Saharan African countries: A multilevel analysis of the recent demographic and health surveyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2335730-2335730 [Peer Reviewed Journal]ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2335730 ;PMID: 38575525Full text available |
11 |
Material Type: Article
|
![]() |
Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the USExpert review of vaccines, 2024-12, Vol.23 (1), p.82-87 [Peer Reviewed Journal]ISSN: 1476-0584 ;EISSN: 1744-8395 ;DOI: 10.1080/14760584.2023.2295014Digital Resources/Online E-Resources |
12 |
Material Type: Article
|
![]() |
Enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in eastern China during the COVID-19 pandemicHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2340765-2340765 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2340765 ;PMID: 38626299Full text available |
13 |
Material Type: Article
|
![]() |
The effectiveness of rural community health workers in improving health outcomes during the COVID-19 pandemic: a systematic reviewGlobal health action, 2024-12, Vol.17 (1), p.2292385 [Peer Reviewed Journal]2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2024 The Author(s) ;ISSN: 1654-9716 ;EISSN: 1654-9880 ;DOI: 10.1080/16549716.2023.2292385 ;PMID: 38180049Full text available |
14 |
Material Type: Article
|
![]() |
Herpes zoster in older adults: Impact on carbon footprint in the United StatesHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2335722-2335722 [Peer Reviewed Journal]2024 GSK. Published with license by Taylor & Francis Group, LLC. 2024 GSK ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2335722 ;PMID: 38698759Full text available |
15 |
Material Type: Article
|
![]() |
Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United StatesHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2303796-2303796 [Peer Reviewed Journal]2024 GSK. Published with license by Taylor & Francis Group, LLC. 2024 GSK ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2303796 ;PMID: 38297921Full text available |
16 |
Material Type: Article
|
![]() |
Regarding "Reply to the enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in Eastern China during the COVID-19 pandemic"Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2354011-2354011 [Peer Reviewed Journal]ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2354011 ;PMID: 38787317Full text available |
17 |
Material Type: Article
|
![]() |
COVID-19 vaccine hesitancy among the Chinese elderly: A multi-stakeholder qualitative studyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2315663-2315663 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2024.2315663 ;PMID: 38439589Full text available |
18 |
Material Type: Article
|
![]() |
Action against birth defects: if not now, when?Global health action, 2024-12, Vol.17 (1), p.2354002-2354002 [Peer Reviewed Journal]2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2024 The Author(s) ;ISSN: 1654-9716 ;EISSN: 1654-9880 ;DOI: 10.1080/16549716.2024.2354002 ;PMID: 38819326Full text available |
19 |
Material Type: Article
|
![]() |
Impact of the COVID-19 pandemic on type 2 diabetes care and factors associated with care disruption in Kenya and TanzaniaGlobal health action, 2024-12, Vol.17 (1), p.2345970-2345970 [Peer Reviewed Journal]EISSN: 1654-9880 ;DOI: 10.1080/16549716.2024.2345970 ;PMID: 38774927Full text available |
20 |
Material Type: Article
|
![]() |
A scoping review of active, participant centred, digital adverse events following immunization (AEFI) surveillance of WHO approved COVID-19 vaccines: A Canadian immunization Research Network studyHuman vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2293550-2293550 [Peer Reviewed Journal]2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s) ;ISSN: 2164-5515 ;EISSN: 2164-554X ;DOI: 10.1080/21645515.2023.2293550 ;PMID: 38374618Full text available |